Focused On-demand Library for Semaphorin-4A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9H3S1

UPID:

SEM4A_HUMAN

Alternative names:

Semaphorin-B

Alternative UPACC:

Q9H3S1; B2RDH8; B3KR76; Q5TCI5; Q5TCJ6; Q8WUA9

Background:

Semaphorin-4A, also known as Semaphorin-B, is a cell surface receptor crucial for cell-cell signaling. It regulates the development of both glutamatergic and GABAergic synapses, influencing the balance between excitatory and inhibitory signals in the brain. Additionally, it plays a pivotal role in adaptive immunity by priming antigen-specific T-cells and promoting Th1 T-helper cell differentiation. Its involvement in inhibiting angiogenesis and axonal extension highlights its multifaceted role in biological systems.

Therapeutic significance:

Given its association with Retinitis pigmentosa 35 and Cone-rod dystrophy 10, Semaphorin-4A represents a promising target for therapeutic intervention. Understanding its role could pave the way for novel treatments for these retinal dystrophies, offering hope for patients suffering from these progressive vision impairments.